The MRDR Steering Committee features some internationally recognised clinical myeloma experts, a clinical myeloma nurse consultant and a patient/carer’s advocate, providing valuable insights on behalf of those living with myeloma.
The MRDR Steering Committee provides advice and guidance in governance of the registry.
Professor Spencer is Head of the Malignant Haematology and Stem Cell Transplantation Service at The Alfred Hospital, Professor of Haematology at Monash University, Head of the Myeloma Research Group and Co-Director of the ACRF Blood Cancer Therapeutics Centre at the Australian Centre for Blood Diseases, all in Melbourne, Australia. He serves on the scientific advisory boards of the International Myeloma Foundation (IMF), International Myeloma Working Group (IMWG) and the European Myeloma Network (EMN).
Professor Wood is a haematologist, and Head of the Transfusion Research Unit at SPHPM, Monash University which operates major registries and clinical trials in transfusion and blood disorders, including haematological malignancies. She is a Consultant Haematologist at Monash Health and honorary Consultant Haematologist at Peter MacCallum Cancer Centre.
Professor Joy Ho is Senior Staff Specialist in Haematology, Institute of Haematology, Royal Prince Alfred Hospital and Clinical Professor, Faculty of Medicine, University of Sydney. She is one of the principal investigators of the Myeloma Research Unit at Royal Prince Alfred Hospital.
A/Prof Peter Mollee is Chair, Myeloma Disease Group, Australasian Leukaemia and Lymphoma Group and Director of the Princess Alexandra Hospital Amyloidosis Clinic. Peter is involved in research generated from local, administrative and cancer registry databases.
Professor John McNeil was head of Monash University’s School of Public Health and Preventive Medicine until recently in 2019. His research background is in epidemiology & clinical pharmacology and he is co-principal investigator of the joint US-Australia NIH-funded ASPREE trial of low-dose aspirin in the elderly, which is the largest prevention trial conducted within Australia and will become a major international resource for study of the elderly. He has extensive experience in clinical registries and research governance.
A/Prof McQuilten is a consultant haematologist and NHMRC Early Career Fellow at Monash University. She is deputy-director of the Transfusion Research Unit at Monash University, Chair of the Supportive Care Disease Group with the Australiasian Leukaemia and Lymphoma Group and member of the Advisory Committee for the Australian Red Cross Blood Service.
A/Prof Hilary Blacklock is a haematologist at Middlemore Hospital, Auckland, New Zealand; Medical Director of the NZ Bone Marrow Donor Registry, and member of the Board of Trustees of Leukaemia and Blood Cancer NZ.
Dr Hang Quach is a consultant haematologist and member of the Australian Medical and Scientific Advisory Group of MFA. Hang has a special interest in biology and immunology of multiple myeloma and novel therapeutics.
Dr Bradley Augustson is a clinical and laboratory haematologist with experience in clinical trials in malignant haematology.
Mr Brian Rosengarten is joint founder and current President of the Myeloma Foundation, Australia.
Ms Tracy King is a clinical research fellow with the Clinical Nursing Research Unit at Sydney University and is an experienced myeloma nurse based at the Royal Prince Alfred Hospital. She established the MFA in NSW, co-founded the HSANZ nurses group and convened the first Nursing Symposium at the International Myeloma Workshop.
Professor Christopher Reid is Associate Director of the Monash Centre of Cardiovascular Research and Education in Therapeutics, and Head of the Clinical Informatics and Data Management Unit at the School of Public Health and Preventive Medicine at Monash University.
A/Prof Simon Harrison is the Director of the Centre of Excellence in Cellular Immunotherapy at the Peter MacCallum Cancer Centre. He is also the lead Haematologist for Myeloma and Director of Clinical Apheresis at Peter Mac, and a clinician scientist in the Sir Peter MacCallum department of Oncology in Melbourne University. His work focuses on the immunopathology of multiple myeloma, the impact of novel drug combinations and immune therapies.
Dr Patricia Walker is a clinical haematologist at Peninsula Private Hospital and the Alfred Hospital. Her ongoing areas of interest include malignant haematology, stem cell transplantation and survivorship/late effects of treatment.
Dr Noemi Horvath is a clinical and laboratory haematologist and head of the Myeloma Research Group at Royal Adelaide Hospital.
Dr Krystal Bergin is a clinical haematologist with Alfred Health who is currently completing a PhD with the Central Clinical School at Monash University.